公开(公告)号：US11407721B2

公开(公告)日：2022-08-09

申请号：US16048677

申请日：2018-07-30

Applicant: AMGEN INC.

Inventor： Michael D. Bartberger ,  Hilary Plake Beck ,  Michael R. Degraffenreid ,  Brian M. Fox ,  Felix Gonzalez Lopez De Turiso ,  Lisa D. Julian ,  Frank Kayser ,  Julio C. Medina ,  Steven H. Olson ,  Yosup Rew ,  Philip M. Roveto ,  Daqing Sun ,  Xuelei Yan

IPC: C07D265/32 ,  C07D413/06 ,  C07D487/04 ,  C07D279/12 ,  C07D413/04

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

公开(公告)号：US11306107B2

公开(公告)日：2022-04-19

申请号：US16078152

申请日：2017-02-24

Applicant: AMGEN INC.

Inventor： Sean P. Brown ,  David Karl Bedke ,  Michael R. Degraffenreid ,  Jiasheng Fu ,  Zhihong Li ,  Felix Gonzalez Lopez De Turiso ,  Ana Gonzalez Buenrostro ,  Michael W. Gribble, Jr. ,  Michael G. Johnson ,  Todd J. Kohn ,  Kexue Li ,  Yunxiao Li ,  Mike Elias Lizarzaburu ,  Yosup Rew ,  Joshua Taygerly ,  Yingcai Wang ,  Xuelei Yan ,  Ming Yu ,  Jiang Zhu ,  Manuel Zancanella ,  Xian Yun Jiao ,  Liusheng Zhu ,  Xianghong Wang ,  Julio C. Medina ,  Jason A. Duquette ,  Jonathan B. Houze ,  Marc Vimolratana ,  Mario G. Cardozo ,  Alan C. Cheng

IPC: C07D513/10 ,  C07D513/20 ,  C07D515/10

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.